Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of Odiparcil in children with Mucopolysaccharidosis VI (MPS VI)

Next Previous
Trial Profile

Phase I/II trial of Odiparcil in children with Mucopolysaccharidosis VI (MPS VI)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odiparcil (Primary)
  • Indications Mucopolysaccharidosis VI
  • Focus Adverse reactions
  • Acronyms SAFE-KIDDS

Most Recent Events

  • 10 Nov 2020 According to an Inventiva Pharma media release, this trial will not be initiated in the first half of 2021 as initially planned.
  • 16 Sep 2020 According to an Inventiva Pharma media release, company decided to extend the duration of this trial evaluating odiparcil following a scientific advice meeting with the EMA in July; launch of the trial is expected in the first half of 2021
  • 07 Feb 2020 According to an Inventiva Pharma media release, the launch of this study is planned for the end of the year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top